研究者詳細 - 柴田　浩行

The long-term impact of the coronavirus disease 2019 (COVID-19) pandemic on the disruption of gastrointestinal cancer diagnoses remains unclear. This study investigated the actual impact on esophagogastric cancer (EGC) and colorectal cancer (CRC) diagnoses up to the third year of the pandemic in Akita Prefecture, Japan, using population-based registry data. We collected data on the annual number of EGC and CRC diagnoses using a database from the collaborative Akita Prefecture hospital-based registration. The net number of cancers diagnosed in the first three years of the pandemic (2020-2022) were compared with those diagnosed in the three years before the pandemic (2017-2019). Changes in the proportion of cancer stage and initial treatment for diagnosed EGC and CRC after the pandemic were then compared. The total number of EGCs was 9.3% lower in the first three years of the pandemic than in the three years before, probably due to its long-term declining trend. The total number of CRCs in the first three years of the pandemic exceeded that in the three years before, suggesting successful recovery of the diagnostic procedure. The proportion of cancer stages and initial treatment for EGCs and CRCs remained largely unchanged after the onset of the pandemic. Based on the population-based registry data from the first three years of the pandemic, the disruption of gastrointestinal cancer diagnoses caused by the pandemic is settling down without any substantial disease progression, even in Akita Prefecture, the area with the highest incidence of cancer in all of Japan.

DOI PubMed CiNii Research

Association between albumin–bilirubin grade and plasma trough concentrations of regorafenib and its metabolites M-2 and M-5 at steady-state in Japanese patients

Fujita K.

Investigational New Drugs ( Investigational New Drugs ) 42 ( 3 ) 252 - 260 2024年06月

DOI

Clinical response of pancreatic cancer bearing a germline BRCA2 p.I3169M fs∗48 variant for platinum-based drug and PARP inhibitor

Akahira R.

Japanese Journal of Clinical Oncology ( Japanese Journal of Clinical Oncology ) 54 ( 2 ) 201 - 205 2024年02月

DOI

Design, Synthesis, and Biological Evaluation of Water-Soluble Prodrugs of C5-Curcuminoid GO-Y030 Based on Reversible Thia-Michael Reaction

Yamakoshi H.

Chemical and Pharmaceutical Bulletin ( Chemical and Pharmaceutical Bulletin ) 72 ( 1 ) 127 - 134 2024年

Although curcumin and its analogs exhibit anticancer activity, they are still not used as anticancer drugs because of their water insolubility and extremely poor bioavailability. This study describes the development of water-soluble prodrugs of GO-Y030, a potent antitumor C5-curcuminoid, in an attempt to enhance its bioavailability. These prodrugs release the parent compound via a retro-thia-Michael reaction. To endow sufficient hydrophilicity onto GO-Y030 via a single thia-Michael reaction of an aqueous entity, we used a modified glycoconjugate with a thiol group. The water-solubilizing motif was installed on GO-Y030 by the thia-Michael reaction of propargyl-polyethylene glycol (PEG)-thiol and subsequent click chemistry (CuAAC) reaction with 1-glycosyl azide. Turbidity measurements revealed a significantly improved water solubility of the prodrugs, demonstrating that disaccharide conjugates were completely dissolved in water at 100 µM. Their cytotoxicity was comparable to that of the parent compound GO-Y030, indicating the gradual in situ release of GO-Y030. The release of GO-Y030 from GO-Y199 via the retro-thia-Michael reaction was demonstrated through a degradation study in water. Our retro-thia-Michael reaction-based prodrug system can be used for targeting cancer cells.

DOI CiNii Research

Curcumin analog GO-Y030 inhibits tumor metastasis and glycolysis

MaruYama T.

Journal of Biochemistry ( Journal of Biochemistry ) 174 ( 6 ) 511 - 518 2023年11月

DOI

Clinical Course of a Rare Epstein-Barr Virus-Associated Smooth Muscle Tumor and Its Genomic Analysis

Miyahara J.

Case Reports in Oncology ( Case Reports in Oncology ) 16 ( 1 ) 577 - 584 2023年08月

DOI

Mono-Carbonyl Curcumin Analogs for Cancer Therapy

MaruYama T.

Biological and Pharmaceutical Bulletin ( Biological and Pharmaceutical Bulletin ) 46 ( 6 ) 756 - 763 2023年06月

Curcumin has long been recognized for its anti-inflammatory properties. An antitumor effect has been recently reported in curcumin and clinical trials are being conducted. However, a large amount of required intake to obtain the antitumor effect of curcumin has been regarded as a problem. Therefore, curcumin analogs have been created by many researchers to enhance the effects of curcumin. We have synthesized >50 curcumin analogs and revealed greater growth suppression of various tumor cells with mono-carbonyl analogs than curcumin. Mechanistically, mono-carbonyl analogs inhibited transcriptional activity (e.g., nuclear factor kappa B, signal transducer, and activator of transcription 3) or activated caspase-3. Additionally, mono-carbonyl analogs of curcumin control tumor cell metabolism. Herein, we summarize the current knowledge about mono-carbonyl curcumin analogs and discuss their potential clinical applications.

DOI PubMed CiNii Research

A curcumin analogue GO-Y030 depletes cancer stem cells by inhibiting the interaction between the HSP70/HSP40 complex and its substrates

Suzuki M.

FEBS Open Bio ( FEBS Open Bio ) 13 ( 3 ) 434 - 446 2023年03月

DOI

Biological Features and Clinical Diagnosis of Bone Metastasis

Shibata H.

Gan to kagaku ryoho. Cancer & chemotherapy ( Gan to kagaku ryoho. Cancer & chemotherapy ) 50 ( 3 ) 283 - 286 2023年03月

Lymph-node metastasis from gastric adenocarcinoma in a patient bearing a germ line missense variant MSH2 c.1808A > T (Asp603Val) responds to the immune checkpoint inhibitor pembrolizumab

Kiyomiya M.

Japanese Journal of Clinical Oncology ( Japanese Journal of Clinical Oncology ) 53 ( 3 ) 270 - 274 2023年03月

DOI

A randomized controlled phase III trial protocol: perioperative pirfenidone therapy in patients with non-small cell lung cancer combined with idiopathic pulmonary fibrosis to confirm the preventative effect against postoperative acute exacerbation: the PIII-PEOPLE study (NEJ034)

Sakairi Y.

Journal of Thoracic Disease ( Journal of Thoracic Disease ) 15 ( 3 ) 1486 - 1493 2023年03月

DOI

Pyrolyzed deketene curcumin controls regulatory T cell generation and gastric cancer metabolism cooperate with 2-deoxy-d-glucose

MaruYama T.

Frontiers in Immunology ( Frontiers in Immunology ) 14 2023年02月

DOI

Pulmonary Artery Intimal Sarcoma in a Patient with Lynch Syndrome: Response to an Immune Checkpoint Inhibitor

Mounai Y.

Case Reports in Oncology ( Case Reports in Oncology ) 16 ( 1 ) 21 - 29 2023年01月

DOI

Efficacy and safety of bone management agents administered at 12 weeks vs. 4 weeks in patients with bone metastases: A systematic review

Sato J.

Journal of Oncology Pharmacy Practice ( Journal of Oncology Pharmacy Practice ) 30 ( 7 ) 1160 - 1172 2023年

DOI

クルクミン類似体GO-Y022はクルクミンよりも低濃度で圧負荷による心機能低下を抑制した

平子裕太, 清水果奈, 船本雅文, 川瀬裕斗, WU HANHAO, 砂川陽一, 刀坂泰史, 清水聡史, 柴田浩行, 長谷川浩二, 森本達也

日本薬理学会年会要旨集 ( 公益社団法人日本薬理学会 ) 95 ( 0 ) 1-SS-34 2022年

国内共著

Background: We previously reported that natural compound curcumin suppresses cardiomyocyte hypertrophy and the development of heart failure via inhibiting p300 histone acetyltransferase (HAT) activity. In this study, we investigated the effect of curcumin analogue, GO-Y022 on p300-HAT activity, cultured cardiomyocyte hypertrophy and heart failure in vivo.Methods & Results: In vitro HAT assay using recombinant p300-HAT domain showed that GO-Y022 inhibited p300-HAT activity as well as curcumin. Primary cultured cardiomyocytes prepared from neonatal rats were treated with curcumin or GO-Y022 and stimulated with phenylephrine (PE). 1 µM GO-Y022 suppressed the following results to the same extent as 10 µM of curcumin: PE-induced histone acetylation, hypertrophic response gene transcription, and cardiomyocyte hypertrophy. Finally, 8-week-old C57BL/6J male mice were subjected to transverse aortic constriction (TAC) surgery and orally administrated GO-Y022 or curcumin for 8 weeks. Cardiac echography indicated that a low dose of GO-Y022 (1 mg/kg) repressed TAC-induced increase in left ventricular posterior wall dimension and decrease in Fractional shortening to the same extent as 50 mg/kg of curcumin. Conclusion: GO-Y022 may be used for heart failure therapy at a lower dose than curcumin.

DOI CiNii Research

クルクミン類似体GO-Y022は心機能低下を改善した

平子裕太, 砂川陽一, 清水果奈, 船本雅文, 刀坂泰史, 浜辺俊英, 柴田浩之, 小見山麻紀, 長谷川浩二, 森本達也

日本薬理学会年会要旨集 ( 公益社団法人日本薬理学会 ) 96 ( 0 ) 3-B-P-214 2022年

【Introduction】We previously found that a natural p300 HAT inhibitor, curcumin (CUR), can inhibit cardiomyocyte hypertrophy and the development of heart failure in vivo. We focused on a CUR analog, GO-Y022, which shows stronger anti-cancer activity than CUR. The purpose of this study was to determine whether GO-Y022 inhibits p300-HAT activity and can be used as a therapeutic agent for heart failure. 【Methods & Results】In vitro HAT assay using recombinant p300-HAT domain showed that GO-Y022 inhibited p300-HAT activity as well as CUR. Primary cultured cardiomyocytes prepared from neonatal rats were treated with GO-Y022 or CUR and then stimulated with phenylephrine (PE) for 48 hours. One µM of GO-Y022 suppressed PE-induced histone H3K9 acetylation, hypertrophic response gene transcription, and cardiomyocyte hypertrophy to the same extent as 10 µM of CUR. C57BL/6j male mice were subjected to transverse aortic constriction (TAC) or sham operation. The TAC mice were randomly assigned to five groups: Vehicle, CUR at 1 or 50 mg/kg, or GO-Y022 at 0.2 or 1 mg/kg. After 8 weeks daily oral treatment, echocardiographic analysis showed that 1 mg/kg of GO-Y022 and 50 mg/kg of CUR improved a TAC-induced increase in left ventricular posterior wall thickness and a decrease in fractional shortening.【Conclusion】These results indicate that GO-Y022 strongly inhibits both PE-induced hypertrophic responses and pressure overload-induced development of heart failure. These findings suggest that GO-Y022 may be a novel candidate agent for heart failure therapy.

DOI CiNii Research

Curcumin analog GO-Y030 boosts the efficacy of anti-PD-1 cancer immunotherapy

MaruYama T.

Cancer Science ( Cancer Science ) 112 ( 12 ) 4844 - 4852 2021年12月

DOI

The Curcumin Analog GO-Y030 Controls the Generation and Stability of Regulatory T Cells

MaruYama T.

Frontiers in Immunology ( Frontiers in Immunology ) 12 2021年06月

DOI

Phase II study of trifluridine/tipiracil (TAS-102) therapy in elderly patients with colorectal cancer (T-CORE1401): geriatric assessment tools and plasma drug concentrations as possible predictive biomarkers

Takahashi M.

Cancer Chemotherapy and Pharmacology ( Cancer Chemotherapy and Pharmacology ) 88 ( 3 ) 393 - 402 2021年